Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2018 Sep 12

PMID 30200467

Citations 11

Authors

Joaquin Cubiella

Marc Clos-Garcia

Cristina Alonso

Ibon Martinez-Arranz

Miriam Perez-Cormenzana

Ziortza Barrenetxea

Jesus Berganza

Isabel Rodriguez-Llopis

Mauro DAmato

Luis Bujanda

Marta Diaz-Ondina

Juan M Falcon-Perez

Affiliations

Soon will be listed here.

Abstract

Low invasive tests with high sensitivity for colorectal cancer and advanced precancerous lesions will increase adherence rates, and improve clinical outcomes. We have performed an ultra-performance liquid chromatography/time-of-flight mass spectrometry (UPLC-(TOF) MS)-based metabolomics study to identify faecal biomarkers for the detection of patients with advanced neoplasia. A cohort of 80 patients with advanced neoplasia (40 advanced adenomas and 40 colorectal cancers) and 49 healthy subjects were analysed in the study. We evaluated the faecal levels of 105 metabolites including glycerolipids, glycerophospholipids, sterol lipids and sphingolipids. We found 18 metabolites that were significantly altered in patients with advanced neoplasia compared to controls. The combinations of seven metabolites including ChoE(18:1), ChoE(18:2), ChoE(20:4), PE(16:0/18:1), SM(d18:1/23:0), SM(42:3) and TG(54:1), discriminated advanced neoplasia patients from healthy controls. These seven metabolites were employed to construct a predictive model that provides an area under the curve (AUC) median value of 0.821. The inclusion of faecal haemoglobin concentration in the metabolomics signature improved the predictive model to an AUC of 0.885. In silico gene expression analysis of tumour tissue supports our results and puts the differentially expressed metabolites into biological context, showing that glycerolipids and sphingolipids metabolism and GPI-anchor biosynthesis pathways may play a role in tumour progression.

Citing Articles

Current Research on Molecular Biomarkers for Colorectal Cancer in Stool Samples.

Ordenes P, Carril Pardo C, Elizondo-Vega R, Oyarce K Biology (Basel). 2024; 13(1).

PMID: 38248446 PMC: 10813333. DOI: 10.3390/biology13010015.

Gut Microbial and Associated Metabolite Markers for Colorectal Cancer Diagnosis.

Alhhazmi A, Alhamawi R, Almisned R, Almutairi H, Jan A, Kurdi S Microorganisms. 2023; 11(8).

PMID: 37630597 PMC: 10457972. DOI: 10.3390/microorganisms11082037.

From Omic Layers to Personalized Medicine in Colorectal Cancer: The Road Ahead.

Romero-Garmendia I, Garcia-Etxebarria K Genes (Basel). 2023; 14(7).

PMID: 37510334 PMC: 10379575. DOI: 10.3390/genes14071430.

A Novel Approach on the Use of Samples from Faecal Occult Blood Screening Kits for Metabolomics Analysis: Application in Colorectal Cancer Population.

Alboniga O, Cubiella J, Bujanda L, Blanco M, Lanza B, Alonso C Metabolites. 2023; 13(3).

PMID: 36984761 PMC: 10055627. DOI: 10.3390/metabo13030321.

A Prognostic Ferroptosis-Related lncRNA Model Associated With Immune Infiltration in Colon Cancer.

Lu J, Tan J, Yu X Front Genet. 2022; 13:934196.

PMID: 36118850 PMC: 9470855. DOI: 10.3389/fgene.2022.934196.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu N . The footprints of gut microbial-mammalian co-metabolism. J Proteome Res. 2011; 10(12):5512-22. DOI: 10.1021/pr2007945. View

Luo W, Brouwer C . Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013; 29(14):1830-1. PMC: 3702256. DOI: 10.1093/bioinformatics/btt285. View

Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y . A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012; 7(7):e40459. PMC: 3394708. DOI: 10.1371/journal.pone.0040459. View

Wang H, Wang L, Zhang H, Deng P, Chen J, Zhou B . ¹H NMR-based metabolic profiling of human rectal cancer tissue. Mol Cancer. 2013; 12(1):121. PMC: 3819675. DOI: 10.1186/1476-4598-12-121. View

Szklarczyk D, Morris J, Cook H, Kuhn M, Wyder S, Simonovic M . The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2016; 45(D1):D362-D368. PMC: 5210637. DOI: 10.1093/nar/gkw937. View

Tan B, Qiu Y, Zou X, Chen T, Xie G, Cheng Y . Metabonomics identifies serum metabolite markers of colorectal cancer. J Proteome Res. 2013; 12(6):3000-9. PMC: 5902797. DOI: 10.1021/pr400337b. View

Zhang F, Zhang Y, Zhao W, Deng K, Wang Z, Yang C . Metabolomics for biomarker discovery in the diagnosis, prognosis, survival and recurrence of colorectal cancer: a systematic review. Oncotarget. 2017; 8(21):35460-35472. PMC: 5471069. DOI: 10.18632/oncotarget.16727. View

Leichtle A, Nuoffer J, Ceglarek U, Kase J, Conrad T, Witzigmann H . Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics. 2012; 8(4):643-653. PMC: 3397217. DOI: 10.1007/s11306-011-0357-5. View

10.

Westwood M, Lang S, Armstrong N, van Turenhout S, Cubiella J, Stirk L . Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Med. 2017; 15(1):189. PMC: 5654140. DOI: 10.1186/s12916-017-0944-z. View

11.

Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A . Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366(8):697-706. DOI: 10.1056/NEJMoa1108895. View

12.

Zhao Y, Wu J, Li J, Zhou N, Tang H, Wang Y . Gut microbiota composition modifies fecal metabolic profiles in mice. J Proteome Res. 2013; 12(6):2987-99. DOI: 10.1021/pr400263n. View

13.

Valcz G, Patai A, Kalmar A, Peterfia B, Furi I, Wichmann B . Myofibroblast-derived SFRP1 as potential inhibitor of colorectal carcinoma field effect. PLoS One. 2014; 9(11):e106143. PMC: 4236006. DOI: 10.1371/journal.pone.0106143. View

14.

Poroyko V, Morowitz M, Bell T, Ulanov A, Wang M, DONOVAN S . Diet creates metabolic niches in the "immature gut" that shape microbial communities. Nutr Hosp. 2012; 26(6):1283-95. DOI: 10.1590/S0212-16112011000600015. View

15.

Tang X, Benesch M, Brindley D . Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. J Lipid Res. 2015; 56(11):2048-60. PMC: 4617392. DOI: 10.1194/jlr.R058362. View

16.

Jump R, Polinkovsky A, Hurless K, Sitzlar B, Eckart K, Tomas M . Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization resistance in clindamycin-treated mice. PLoS One. 2014; 9(7):e101267. PMC: 4079339. DOI: 10.1371/journal.pone.0101267. View

17.

Puente Gutierrez J, Marin Moreno M, Dominguez Jimenez J, Bernal Blanco E, Diaz Iglesias J . Effectiveness of a colonoscopic screening programme in first-degree relatives of patients with colorectal cancer. Colorectal Dis. 2011; 13(6):e145-53. DOI: 10.1111/j.1463-1318.2011.02577.x. View

18.

Weir T, Manter D, Sheflin A, Barnett B, Heuberger A, Ryan E . Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One. 2013; 8(8):e70803. PMC: 3735522. DOI: 10.1371/journal.pone.0070803. View

19.

Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T . Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2011; 26(5):548-58. DOI: 10.1002/bmc.1671. View

20.

Gao X, Pujos-Guillot E, Sebedio J . Development of a quantitative metabolomic approach to study clinical human fecal water metabolome based on trimethylsilylation derivatization and GC/MS analysis. Anal Chem. 2010; 82(15):6447-56. DOI: 10.1021/ac1006552. View